Skip to main content
PGEN
NASDAQ Life Sciences

Controlling Shareholder Randal J. Kirk Sells $15.75 Million in Precigen Stock

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
9
Price
$3.89
Mkt Cap
$1.37B
52W Low
$1.11
52W High
$5.465
Market data snapshot near publication time

summarizeSummary

Randal J. Kirk, a Director and controlling shareholder of Precigen, Inc., sold 4.77 million shares of common stock for $15.75 million, following a concurrent Schedule 13D/A filing reporting the same disposition.


check_boxKey Events

  • Significant Insider Sale

    Randal J. Kirk, a Director and controlling shareholder, sold 4,772,781 shares of Precigen common stock.

  • Substantial Value

    The total value of the shares sold amounted to $15,750,177.

  • Timing with Prior Disclosure

    This Form 4 provides the detailed transaction data for the sale previously reported in a Schedule 13D/A filed on the same day.

  • Context of Financial Performance

    The sale follows the company's recent report of a significant net loss for 2025 and the securing of $100 million in debt.


auto_awesomeAnalysis

This Form 4 details the significant sale of Precigen shares by Randal J. Kirk, a Director and controlling shareholder, which was also reported in a concurrent Schedule 13D/A. The disposition of over $15.75 million worth of stock, representing 1.15% of the company's market capitalization, by a key insider and controlling figure, sends a strong negative signal to the market. This transaction occurs shortly after the company reported a substantial net loss for 2025 and secured additional debt, raising concerns about insider confidence amidst financial challenges. Investors should note the scale of this sale by a major stakeholder.

At the time of this filing, PGEN was trading at $3.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $1.11 to $5.47. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed PGEN - Latest Insights

PGEN
Apr 07, 2026, 7:00 AM EDT
Source: Access Newswire
Importance Score:
9
PGEN
Mar 31, 2026, 4:10 PM EDT
Filing Type: 4
Importance Score:
9
PGEN
Mar 31, 2026, 4:01 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
PGEN
Mar 25, 2026, 4:54 PM EDT
Filing Type: 10-K
Importance Score:
8
PGEN
Mar 25, 2026, 4:53 PM EDT
Source: Wiseek News
Importance Score:
8
PGEN
Mar 25, 2026, 4:52 PM EDT
Filing Type: 8-K
Importance Score:
8
PGEN
Mar 25, 2026, 4:05 PM EDT
Source: Dow Jones Newswires
Importance Score:
8